Results 131 to 140 of about 3,264 (192)

A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target. [PDF]

Front Med (Lausanne)
Didona D, Mariotti F, Pira A, Didona B, Hertl M, Di Zenzo G.   +5 more
europepmc   +1 more source

Localized bullous pemphigoid masquerading as venous leg ulcers in a patient with chronic venous insufficiency. [PDF]

JAAD Case Rep
Perry A, Namazian S, Vu T, Mervis J.
europepmc   +1 more source

Recurrent Bullous Pemphigoid: A Case Report. [PDF]

Cureus
Gowda Venkatesha RR, Rajaram Mohan K, Aravind M, Sridharrao V, Chandran N.   +4 more
europepmc   +1 more source

Lichen Planus Pemphigoides in Childhood. [PDF]

Indian Dermatol Online J
Srinivasan H, Kanagarajan A, Rai R, Shanmugasundaram S.   +3 more
europepmc   +1 more source

Granular C3 Dermatosis With Intraepidermal Blister Formation. [PDF]

J Dermatol
Tezuka J, Tanabe H.
europepmc   +1 more source

Regulation Mechanism for the movement of BP180, A transmembrane protein of the hemidesmosome.

Seibutsu Butsuri, 1999
K. Murase, Y. Hirako, K. Owaribe, A. Kusumi   +3 more
openaire   +2 more sources

Stapokibart's clinical effectiveness in treating moderate-to-severe bullous pemphigoid in the elderly. [PDF]

Front Immunol
Du N, Wang Y, Yang J, Lv X, Min W.
europepmc   +1 more source

Vedolizumab-induced Bullous Pemphigoid: A Case Report with Serological Evidence and Mechanistic Insights. [PDF]

Acta Derm Venereol
Feng X, Li J, Li X, Zhang Y, Li W.
europepmc   +1 more source

Thematic Evolution and Diversification of Bullous Pemphigoid Research: A Bibliometric Analysis, 1959-2025. [PDF]

Clin Cosmet Investig Dermatol
Lu MC, Chiu MC, Koo M.
europepmc   +1 more source

Regulatory T cells in bullous pemphigoid: biological characteristics, dysfunction, and pathogenic roles. [PDF]

Front Immunol
Wang Z, Lu Y, Cui H, Zhang Y, Meng L, Chang W, Yang X, Ye J.   +7 more
europepmc   +1 more source